2021. Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s19. DOI:https://doi.org/10.25251/skin.5.supp.19.